← Back to Search

Small Molecule Drug

MRTX849 for Colon Cancer

Phase 1

Waitlist Available

Research Sponsored by Mirati Therapeutics Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 20 months

Awards & highlights

Study Summary

This trial will study the safety and effectiveness of a new KRAS cancer drug.

Eligible Conditions

Cancer
Colon Cancer
Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 20 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~20 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation

Establish Maximum Tolerated Dose

Evaluate Pharmacokinetics of the combination regimen

Secondary outcome measures

Evaluate preliminary clinical activity of the combination regimen

Trial Design

2Treatment groups

Experimental Treatment

Group I: Dose expansionExperimental Treatment2 Interventions

Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963

Group II: Dose escalationExperimental Treatment2 Interventions

Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MRTX849

2021

Completed Phase 1

~10

BI 1701963

2021

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor

69 Previous Clinical Trials

7,978 Total Patients Enrolled

Boehringer IngelheimIndustry Sponsor

2,499 Previous Clinical Trials

11,339,759 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this particular experiment an unprecedented endeavor?

"Mirati Therapeutics Inc.'s MRTX849 has seen 6 trials in 247 cities and 33 countries since 2019. Thus far, the first trial of this drug, involving 740 patients and culminating with Phase 1 & 2 approval stages, is the only one to have been successfully concluded."

Answered by AI

How many facilities are conducting this experiment?

"At present, 4 different medical facilities are in the process of enrolling patients into this trial: MD Anderson Cancer Center (Houston), The Cleveland Clinic Foundation (Cleveland), and Next Oncology (San Antonio) amongst others."

Answered by AI

Has MRTX849 been accorded regulatory endorsement by the FDA?

"Limited efficacy and safety data of MRTX849 has resulted in it receiving a score of 1 on our rating system. This is because this trial lies within the initial stage, phase one."

Answered by AI

Have any prior attempts been made to test the efficacy of MRTX849?

"MRTX849 was initially studied in 2019 at Charleston Oncology P.A.. As of present, there has been no evidence-backed studies done to prove its efficacy; however, 6 clinical trials are currently running with most being located in San Antonio, Texas."

Answered by AI

How many individuals are taking part in this investigation?

"Unfortunately, this research project has stopped recruiting participants since its last update on April 4th 2022. However, at present there are 4613 cancer studies and 6 trials involving MRTX849 actively looking for enrollees."

Answered by AI

What is the current availability of slots for participants in this study?

"According to the clinicaltrials.gov website, this particular medical trial is not currently enrolling patients; while first posted on August 12th 2021 and last updated April 4th 2022. However, there are a wealth of other trials that require volunteers right now with 4619 active studies seeking applicants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

2021. "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04975256.